---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-021514"
form_type: "8-K"
ticker: "ARDX"
cik: "0001437402"
company_name: "ARDELYX, INC."
filed_at: "2025-05-01T23:59:59+00:00"
generated_at: "2026-05-23T00:10:47.250477+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Ardelyx reports Q1 2025 total revenue $74.1M (+61% YoY); IBSRELA $44.4M, XPHOZAH $23.4M

## Summary
- Total revenue $74.1M (+61% YoY); net loss $41.1M ($0.17 loss per share) vs $26.5M loss in Q1 2024.
- IBSRELA net product sales $44.4M (+57% YoY); FY2025 guidance reaffirmed at $240–250M.
- XPHOZAH net product sales $23.4M (+30% ex-returns reserve); $5.0M milestone from Fosun for China tenapanor approval.
- Cash $214.0M (Dec 2024: $250.1M); SG&A $83.2M, R&D $14.9M.
- Appointed Merdad Parsey to Board and Laura Williams as Chief Patient Officer in April 2025.

## SEC filing metadata
- accession: 0001628280-25-021514
- form_type: 8-K
- ticker: ARDX
- cik: 0001437402
- company_name: ARDELYX, INC.
- filed_at: 2025-05-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1437402/000162828025021514/0001628280-25-021514-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1437402/000162828025021514/ardx-20250501.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-021514
- JSON: https://secwatch.observer/filing/0001628280-25-021514.json
- Plain text: https://secwatch.observer/filing/0001628280-25-021514.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.